Pharmacological Management of Coagulation

Aspirin covalently acetylates a specific serine residue (Ser529) in the active site of cyclooxygenase-1, rendering it permanently inactive. Because platelets are anucleate and cannot synthesize new cyclooxygenase-1 protein, once their cyclooxygenase-1 is acetylated they remain permanently inhibited for the remainder of their lifespan (approximately 7 to 10 days). Cyclooxygenase-1 catalyzes the conversion of arachidonic acid to prostaglandin H2, the precursor for thromboxane A2 synthesis. By eliminating cyclooxygenase-1 activity, aspirin abolishes thromboxane A2 production and the thromboxane A2-mediated amplification of platelet activation. Aspirin does not block adenosine diphosphate-mediated (P2Y12) activation, thrombin (protease-activated receptor 1/4) activation, or glycoprotein IIb/IIIa-dependent aggregation — its antiplatelet effect is confined to the thromboxane A2 pathway, which is why it is combined with a P2Y12 inhibitor in high-risk settings.

At low doses (75 to 100 mg per day), aspirin produces near-complete suppression of platelet thromboxane A2 (greater than 95% inhibition) with relatively sparing of vascular endothelial prostacyclin synthesis. This selectivity is lost at higher doses (325 mg or above), where endothelial prostacyclin production is also substantially inhibited. A meta-analysis of over 100,000 patients demonstrated that low-dose aspirin is as effective as higher doses for secondary prevention of vascular events while producing less gastrointestinal bleeding. For acute settings such as acute coronary syndrome, an initial loading dose of 162 to 325 mg achieves rapid cyclooxygenase-1 inhibition before transitioning to low-dose maintenance.

Clopidogrel is a thienopyridine prodrug requiring two-step hepatic cytochrome P450 biotransformation to generate an active thiol metabolite that irreversibly binds the P2Y12 receptor by forming a disulfide bond with cysteine residues in the receptor extracellular domain. Only approximately 15% of an absorbed clopidogrel dose undergoes productive bioactivation; the remainder is hydrolyzed to an inactive metabolite. This inefficient bioactivation pathway makes clopidogrel's antiplatelet effect highly dependent on cytochrome P450 2C19 activity. The standard maintenance dose is 75 mg once daily; loading doses of 300 mg or 600 mg are used when rapid platelet inhibition is needed.

Cytochrome P450 2C19 is highly polymorphic. Patients carrying loss-of-function alleles (particularly CYP2C19*2 and CYP2C19*3) are intermediate or poor metabolizers who demonstrate substantially reduced active metabolite exposure and platelet inhibition. Multiple retrospective analyses and prospective substudies demonstrated that cytochrome P450 2C19 poor and intermediate metabolizers have significantly higher rates of major adverse cardiovascular events including stent thrombosis when treated with clopidogrel after percutaneous coronary intervention. The US Food and Drug Administration issued a boxed warning for clopidogrel regarding poor metabolizer status.

Prasugrel is a third-generation thienopyridine prodrug with faster, more efficient, and less cytochrome P450 2C19-dependent bioactivation than clopidogrel. Onset of platelet inhibition is faster (approximately 30 minutes versus 2 to 4 hours for a 600 mg clopidogrel load), and the degree of inhibition is greater and less variable. A randomized trial (TRITON-TIMI 38, n = 13,608) demonstrated prasugrel reduced the primary composite endpoint by 19% compared to clopidogrel in acute coronary syndrome patients undergoing percutaneous coronary intervention, but with significantly more major bleeding. Prasugrel is contraindicated in patients with prior stroke or transient ischemic attack, and generally avoided in patients aged 75 or older and those weighing less than 60 kilograms.

Ticagrelor is a direct-acting, reversible P2Y12 antagonist that does not require metabolic activation. It binds an allosteric site distinct from the adenosine diphosphate binding site. Onset of action is faster than prasugrel (peak platelet inhibition within 2 hours), and the offset is also faster due to reversible binding, with platelet function recovering within 24 to 48 hours of the last dose. A large randomized trial (PLATO, n = 18,624) demonstrated ticagrelor 90 mg twice daily reduced the composite of cardiovascular death, myocardial infarction, or stroke by 16% compared to clopidogrel in acute coronary syndrome, with a significant reduction in cardiovascular mortality. Unique adverse effects include dyspnea (in approximately 13 to 15% of patients, attributed to adenosine reuptake inhibition) and ventricular pauses on Holter monitoring.

Cangrelor is an intravenous adenosine triphosphate analogue that directly and reversibly inhibits P2Y12 with virtually immediate onset and rapid offset (platelet function returns to baseline within 60 to 90 minutes of stopping the infusion). Its clinical niche is achieving potent, titratable, rapidly reversible P2Y12 inhibition during percutaneous coronary intervention in patients who have not been pre-loaded with an oral P2Y12 inhibitor. When transitioning from cangrelor to oral agents, clopidogrel and prasugrel must be given after the cangrelor infusion ends (not during, because cangrelor occupies P2Y12 and blocks thienopyridine metabolite binding), whereas ticagrelor can be given during the infusion.

For patients who receive a drug-eluting stent after acute coronary syndrome (whether ST-elevation myocardial infarction or non-ST-elevation myocardial infarction), at least 12 months of dual antiplatelet therapy with aspirin plus a P2Y12 inhibitor is recommended. Prolonged dual antiplatelet therapy beyond 12 months is considered in patients who have tolerated therapy without bleeding complications and have high ischemic and low bleeding risk. For elective percutaneous coronary intervention with drug-eluting stent implantation, the minimum recommended duration is 6 months, with shorter durations of 1 to 3 months acceptable in patients at high bleeding risk who received new-generation stents. The minimum duration rationale is prevention of stent thrombosis — a catastrophic complication with 20 to 45% mortality that occurs most commonly within 30 days of stent implantation.

A series of randomized trials has established P2Y12 monotherapy after a brief dual antiplatelet therapy period as a viable alternative to aspirin-based dual antiplatelet therapy in selected patients undergoing percutaneous coronary intervention. The conceptual basis is that aspirin contributes disproportionately to gastrointestinal bleeding risk relative to ischemic protection in the maintenance phase following the initial high-risk post-stent period, while P2Y12 inhibition provides more relevant protection against stent thrombosis. A randomized trial (TWILIGHT, n = high-risk percutaneous coronary intervention patients) demonstrated that ticagrelor plus placebo versus ticagrelor plus aspirin after 3 months of dual antiplatelet therapy reduced clinically relevant bleeding by 44% without increasing the composite ischemic endpoint at 1 year. Current practice favors aspirin discontinuation while maintaining the P2Y12 inhibitor as the preferred de-escalation sequence.